CN108495631A - 联合抗菌组合物以及短疗程抗菌方案 - Google Patents

联合抗菌组合物以及短疗程抗菌方案 Download PDF

Info

Publication number
CN108495631A
CN108495631A CN201680073150.2A CN201680073150A CN108495631A CN 108495631 A CN108495631 A CN 108495631A CN 201680073150 A CN201680073150 A CN 201680073150A CN 108495631 A CN108495631 A CN 108495631A
Authority
CN
China
Prior art keywords
linezolid
months
treatment
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680073150.2A
Other languages
English (en)
Chinese (zh)
Inventor
K·小姆德鲁里
C·M·孟德尔
E·努额姆伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Alliance for TB Drug Development Inc
Original Assignee
Global Alliance for TB Drug Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58518568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108495631(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Global Alliance for TB Drug Development Inc filed Critical Global Alliance for TB Drug Development Inc
Priority to CN202210425060.2A priority Critical patent/CN114796231A/zh
Publication of CN108495631A publication Critical patent/CN108495631A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680073150.2A 2015-10-14 2016-10-05 联合抗菌组合物以及短疗程抗菌方案 Pending CN108495631A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210425060.2A CN114796231A (zh) 2015-10-14 2016-10-05 联合抗菌组合物以及短疗程抗菌方案

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562241280P 2015-10-14 2015-10-14
US62/241,280 2015-10-14
PCT/US2016/055414 WO2017066053A1 (en) 2015-10-14 2016-10-05 Combination antibacterial composition and short-course antibacterial regimen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210425060.2A Division CN114796231A (zh) 2015-10-14 2016-10-05 联合抗菌组合物以及短疗程抗菌方案

Publications (1)

Publication Number Publication Date
CN108495631A true CN108495631A (zh) 2018-09-04

Family

ID=58518568

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680073150.2A Pending CN108495631A (zh) 2015-10-14 2016-10-05 联合抗菌组合物以及短疗程抗菌方案
CN202210425060.2A Pending CN114796231A (zh) 2015-10-14 2016-10-05 联合抗菌组合物以及短疗程抗菌方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210425060.2A Pending CN114796231A (zh) 2015-10-14 2016-10-05 联合抗菌组合物以及短疗程抗菌方案

Country Status (15)

Country Link
US (3) US20180280401A1 (enExample)
EP (2) EP3362068B1 (enExample)
JP (5) JP6845233B2 (enExample)
KR (2) KR20240137128A (enExample)
CN (2) CN108495631A (enExample)
AU (3) AU2016338637A1 (enExample)
BR (1) BR112018007625A2 (enExample)
CA (1) CA3001309C (enExample)
EA (1) EA201890614A1 (enExample)
ES (1) ES2972618T3 (enExample)
HK (1) HK1254620A1 (enExample)
HR (1) HRP20240309T1 (enExample)
PL (1) PL3362068T3 (enExample)
WO (1) WO2017066053A1 (enExample)
ZA (1) ZA201802236B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109387594A (zh) * 2017-08-08 2019-02-26 武汉武药科技有限公司 一种分离和分析贝达喹啉光学异构体的方法
CN117083278A (zh) * 2021-02-01 2023-11-17 结核病药物开发全球联盟公司 普托马尼无定形形式
CN117137918A (zh) * 2023-09-28 2023-12-01 深圳国家感染性疾病临床医学研究中心 一种药物组合物及其应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1254620A1 (zh) * 2015-10-14 2019-07-26 结核病药物开发全球联盟公司 联合抗菌组合物以及短疗程抗菌方案
RS65207B1 (sr) 2017-07-14 2024-03-29 Janssen Pharmaceutica Nv Formulacije bedakvilina sa dugim delovanjem
WO2021016012A1 (en) * 2019-07-19 2021-01-28 The Global Alliance For Tb Drug Development, Inc. Pretomanid compositions
WO2021257461A1 (en) * 2020-06-15 2021-12-23 Mylan Laboratories Limited Combination antibacterial composition and method for antibacterial therapy
WO2021257466A1 (en) * 2020-06-15 2021-12-23 The Global Alliance For Tb Drug Development, Inc. Combination antibacterial composition and method for antibacterial therapy
GB202009684D0 (en) * 2020-06-26 2020-08-12 Viiv Healthcare Co Formulations
WO2025017047A1 (en) 2023-07-18 2025-01-23 Janssen Pharmaceutica Nv Combination products of at least three antibiotics comprising bedaquiline, pretomanid or delamanid, and a cytochrome bc1 inhibitor, and their use in the treatment of mycobacterial infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7889101B2 (en) * 2008-04-14 2011-02-15 Alpine Electronics, Inc Method and apparatus for generating location based reminder message for navigation system
NZ591169A (en) 2008-09-03 2012-12-21 Pfizer Combination therapy for tuberculosis
WO2011139832A2 (en) * 2010-04-28 2011-11-10 Rib-X Pharmaceuticals, Inc. Method for treating mycobacterial infections
HK1254620A1 (zh) 2015-10-14 2019-07-26 结核病药物开发全球联盟公司 联合抗菌组合物以及短疗程抗菌方案

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109387594A (zh) * 2017-08-08 2019-02-26 武汉武药科技有限公司 一种分离和分析贝达喹啉光学异构体的方法
CN109387594B (zh) * 2017-08-08 2021-01-19 武汉武药科技有限公司 一种分离和分析贝达喹啉光学异构体的方法
CN117083278A (zh) * 2021-02-01 2023-11-17 结核病药物开发全球联盟公司 普托马尼无定形形式
CN117137918A (zh) * 2023-09-28 2023-12-01 深圳国家感染性疾病临床医学研究中心 一种药物组合物及其应用

Also Published As

Publication number Publication date
KR20180063318A (ko) 2018-06-11
CA3001309A1 (en) 2017-04-20
EP3362068B1 (en) 2023-12-20
US20200237770A1 (en) 2020-07-30
WO2017066053A1 (en) 2017-04-20
HRP20240309T1 (hr) 2024-05-10
JP7221922B2 (ja) 2023-02-14
EP4324824A2 (en) 2024-02-21
BR112018007625A2 (pt) 2018-10-30
KR102706436B1 (ko) 2024-09-12
US20180280401A1 (en) 2018-10-04
JP2024053045A (ja) 2024-04-12
ES2972618T3 (es) 2024-06-13
AU2021258039A1 (en) 2021-11-25
HK1254620A1 (zh) 2019-07-26
US20230414625A1 (en) 2023-12-28
ZA201802236B (en) 2022-07-27
CN114796231A (zh) 2022-07-29
EP4324824A3 (en) 2024-05-08
EA201890614A1 (ru) 2019-02-28
CA3001309C (en) 2023-12-19
EP3362068C0 (en) 2023-12-20
JP2021038257A (ja) 2021-03-11
EP3362068A4 (en) 2019-06-19
AU2021258039B2 (en) 2024-02-08
JP2018530578A (ja) 2018-10-18
AU2024203012B2 (en) 2025-07-10
KR20240137128A (ko) 2024-09-19
AU2024203012A1 (en) 2024-05-23
JP2024167369A (ja) 2024-12-03
AU2016338637A1 (en) 2018-04-26
PL3362068T3 (pl) 2024-06-24
JP6845233B2 (ja) 2021-03-17
JP2022082753A (ja) 2022-06-02
EP3362068A1 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
AU2024203012B2 (en) Combination antibacterial composition and short-course antibacterial regimen
Protopopova et al. In search of new cures for tuberculosis
EP3003307B1 (en) Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
Asif et al. Quinolone derivatives as antitubercular drugs
RU2663289C2 (ru) Производные фенотиазина и их применение против туберкулеза
JP2015521617A5 (enExample)
EP2461805B1 (en) Spectinamides as anti-tuberculosis agents
CL2024001520A1 (es) Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales
CA2624497C (en) Antituberculosis drug combination comprising oxazole compounds
WO2017030605A2 (en) Tablet composition for anti-tuberculosis antibiotics
Gothi et al. Resistant TB: newer drugs and community approach
EP4108244A1 (en) Ss-lactam antibiotic with significant activity against cancer e.g. colon malignancies
EP1750765B1 (en) Antimycobacterial pharmaceutical composition comprising an antitubercular drug
EA050473B1 (ru) Комбинированная антибактериальная композиция и короткий курс антибактериальной терапии
Semenya Recent Advances in Repositioning Non-Antibiotics against Tuberculosis and other Neglected Tropical Diseases
Alghamdi et al. Recent Developments in Structurally Diverse Anti-Tubercular Drug Molecules and Their Molecular Targets Against Mycobacterium tuberculosis
WO2025017047A1 (en) Combination products of at least three antibiotics comprising bedaquiline, pretomanid or delamanid, and a cytochrome bc1 inhibitor, and their use in the treatment of mycobacterial infections
NZ741833A (en) Liquid dispensing system
Kazmi New drugs for TB
HK1223305B (en) Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
KR20110127219A (ko) 결핵 치료용 화합물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1254620

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20180904

RJ01 Rejection of invention patent application after publication